已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting

医学 伊德里希 苯达莫司汀 美罗华 内科学 肿瘤科 慢性淋巴细胞白血病 伊布替尼 淋巴瘤 奥图穆马 临床研究阶段
作者
Paolo Ghia,Davide Rossi,Emmanuelle Ferrant,Fátima de la Cruz Vicente,Dai Maruyama,Versha Banerji,Patrick Wayne Cobb,Swathi Namburi,Richard Greil,Jeff Porter Sharman,Lisa M. Hess,Nalin Payakachat,Naleen Raj Bhandari,Amy S. Ruppert,Denise Wang,Paolo Abada,Angély Loubert,Kristin Creel,Carol Qiao,Yimei Han
出处
期刊:Journal of Geriatric Oncology [Elsevier BV]
卷期号:17 (6): 103024-103024 被引量:1
标识
DOI:10.1016/j.jgo.2026.103024
摘要

Introdcution The phase 3, randomized trial BRUIN CLL-321 assessed the safety and efficacy of pirtobrutinib versus investigators choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) previously treated with a covalent BTK inhibitor. BRUIN CLL-321 showed significantly improved progression-free survival with pirtobrutinib compared to IdealR/BR. We report secondary endpoints including time to worsening (TTW) of CLL/SLL-related symptoms and physical function (PF). Materials and Methods Patients with relapsed/refractory CLL/SLL who received at least one prior cBTKi were enrolled in BRUIN CLL-321. Exploratory endpoints were evaluated using mixed models for repeated measures analysis for within- and between-group differences. Patient-reported outcomes (PROs) were collected every 4 weeks during study treatment through week 25 on both arms. TTW was evaluated using log rank test and Cox proportional hazards model. The statistical testing of PRO endpoints was not type-1 error controlled and thus descriptive in nature. Results A total of 119 patients were randomized to each treatment arm ( N = 238). Median TTW in CLL/SLL-related symptoms (HR,0.972 [95%CI, 0.461–2.048; p = 0.89) and PF (HR, 0.590 [95%CI, 0.262–1.326]; p = 0.33) was not reached in either treatment arm. Pirtobrutinib demonstrated clinically meaningful improvements from baseline in CLL/SLL-related symptoms, PF, and fatigue at all post-baseline assessments (least squares [LS] means change ranged from −7.0 to −11.8, +5.4 to +8.9, and − 7.0 to −12.7, respectively). Comparing between groups, CLL/SLL-related symptoms were clinically meaningfully lower in the pirtobrutinib group versus IdelaR/BR at Week 9 (LSM d ,-7.3 [standard error (SE), 2.2]), Week 13 (LSM d ,-6.7 [SE, 2.3]), Week 17 (LSM d ,-4.6 [SE, 2.3]), and Week 21 (LSM d ,-7.0 [SE, 2.3]). Patients receiving pirtobrutinib reported better PF versus IdelaR/BR at Weeks 13 (LSM d ,5.6 [SE, 2.4]) and 21 (LSM d ,5.9 [SE, 2.5]). Patients receiving pirtobrutinib also reported clinically meaningful lower fatigue versus IdelaR/BR at Week 9 (LSM d ,-9.0 [SE, 2.9]), Week 13 (LSM d ,-6.7 [SE, 3.0]), and Week 21 (LSM d ,-6.9 [SE, 3.1]). Discussion These analyses demonstrate clinically meaningful improvements for pirtobrutinib at all post-baseline assessments for CLL/SLL-related symptoms, PF, and fatigue. Consistent benefit was seen in CLL/SLL-related symptoms, PF, and fatigue with pirtobrutinib versus IdelaR/BR, with most PRO assessments meeting clinically meaningful differences between groups.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
碧蓝黎云完成签到,获得积分10
2秒前
abou完成签到 ,获得积分10
6秒前
叶也完成签到,获得积分10
6秒前
螺丝炒钉子完成签到,获得积分10
7秒前
锅巴完成签到 ,获得积分10
11秒前
李健的应助被u183311采纳,获得10
14秒前
xiaoming完成签到,获得积分10
14秒前
kane浅完成签到,获得积分10
15秒前
che完成签到,获得积分10
16秒前
高高笙完成签到,获得积分10
16秒前
qq发布了新的文献求助10
17秒前
18秒前
20秒前
青云完成签到,获得积分10
20秒前
22秒前
白华苍松发布了新的文献求助10
23秒前
徐XU发布了新的文献求助10
23秒前
syvshc的应助被00hello00采纳,获得10
26秒前
学霸业的应助被kk采纳,获得10
26秒前
李健的粉丝团团长的应助被kk采纳,获得10
26秒前
洋洋得意发布了新的文献求助10
27秒前
eghiefefe完成签到,获得积分10
28秒前
28秒前
万能图书馆的应助被u183311采纳,获得10
29秒前
29秒前
单身的擎完成签到,获得积分10
32秒前
在水一方的应助被u183311采纳,获得10
32秒前
卡拉肖克攀完成签到 ,获得积分10
33秒前
诤心完成签到 ,获得积分10
33秒前
syvshc的应助被u183311采纳,获得10
34秒前
34秒前
yingyingyangyang完成签到,获得积分10
34秒前
fhg完成签到 ,获得积分10
35秒前
傅jh发布了新的文献求助10
35秒前
随机科研完成签到,获得积分10
36秒前
香蕉觅云的应助被想活在梦里采纳,获得10
38秒前
星辰大海的应助被vivid采纳,获得10
38秒前
38秒前
徐嘻嘻完成签到 ,获得积分10
38秒前
牵着蜗牛散步完成签到 ,获得积分10
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194875
求助须知:如何正确求助?哪些是违规求助? 9580673
关于积分的说明 21872175
捐赠科研通 7794572
什么是DOI,文献DOI怎么找? 3437801
关于科研通互助平台的介绍 2561122
邀请新用户注册赠送积分活动 2484511